BioNova Submits Investigational New Drug Application for BN104 for the Treatment of Acute Leukemia in China
SHANGHAI, China, May. 24, 2023 - BioNova today announced that it has submitted an investigational new drug (IND) application for BN104 for the treatment of relapsed/refractory (R/R) acute leukemia to the China National Medical Products Administration (NMPA).
